Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg.
Monoclonal antibody
Type
Whole antibody
Source
Human
Target
Interferon α
Clinical data
ATC code
none
Identifiers
CAS Number
1006877-41-3Y
ChemSpider
none
UNII
XOY1YA7RMC
KEGG
D09668
Chemical and physical data
Formula
C6518H10008N1724O2032S38
Molar mass
146252.08 g·mol−1
NY (what is this?)(verify)
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1] It targets interferon a.[2]
Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[3][4][5]
^Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B (January 2017). "Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus". Immunotherapy. 9 (1): 57–70. doi:10.2217/imt-2016-0090. PMID 28000522.
^"Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
^"Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
^"Sifalimumab". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 July 2017.
^"Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a. Sifalimumab...
C6518H10008N1724O2032S38 (molar mass: 146250.008 g/mol) may refer to: Sifalimumab Tabalumab This set index page lists chemical structure articles associated...
MedImmune, a unit of AstraZeneca, which chose to move anifrolumab instead of sifalimumab into phase III trials for lupus in 2015. On 16 December 2021, the Committee...
Global Information
(what is this?) (verify)